Suppr超能文献

基于预测糖肽组学的 50 种血清糖蛋白的位点特异性糖基化定量分析可提高疾病生物标志物的发现。

Site-Specific Glycosylation Quantitation of 50 Serum Glycoproteins Enhanced by Predictive Glycopeptidomics for Improved Disease Biomarker Discovery.

机构信息

Department of Chemistry , University of California , One Shields Avenue , Davis , California 95616 , United States.

Department of Dermatology , University of California Davis, School of Medicine , Sacramento , California 95817 , United States.

出版信息

Anal Chem. 2019 Apr 16;91(8):5433-5445. doi: 10.1021/acs.analchem.9b00776. Epub 2019 Mar 27.

Abstract

Analysis of serum protein glycovariants has the potential to identify new biomarkers of human disease. However, the inability to rapidly quantify glycans in a site-specific fashion remains the major barrier to applying such biomarkers clinically. Advancements in sample preparation and glycopeptide quantification are thus needed to better bridge glycoscience with biomarker discovery research. We present here the successful utilization of several sample preparation techniques, including multienzyme digestion and glycopeptide enrichment, to increase the repertoire of glycopeptides that can be generated from serum glycoproteins. These techniques combined with glycopeptide retention time prediction and UHPLC-QqQ conditions optimization were then used to develop a dynamic multiple-reaction monitoring (dMRM)-based strategy to simultaneously monitor over 100 glycosylation sites across 50 serum glycoproteins. In total, the abundances of over 600 glycopeptides were simultaneously monitored, some of which were identified by utilizing theoretically predicted ion products and presumed m/ z values. The dMRM method was found to have good sensitivity. In the targeted dMRM mode, the limit of quantitation (LOQ) of nine standard glycoproteins reached femtomole levels with dynamic ranges spanning 3-4 orders of magnitude. The dMRM-based strategy also showed high reproducibility with regards to both instrument and sample preparation performance. The high coverage of the serum glycoproteins that can be quantitated to the glycopeptide level makes this method especially suitable for the biomarker discovery from large sample sets. We predict that, in the near future, biomarkers, such as these, will be deployed clinically, especially in the fields of cancer and autoimmunity.

摘要

血清蛋白糖型分析具有鉴定人类疾病新生物标志物的潜力。然而,无法快速以特定方式定量糖基化仍然是将此类生物标志物应用于临床的主要障碍。因此,需要在样品制备和糖肽定量方面取得进展,以更好地将糖科学与生物标志物发现研究联系起来。我们在此介绍了几种样品制备技术(包括多酶消化和糖肽富集)的成功应用,这些技术可增加可从血清糖蛋白中产生的糖肽的种类。然后,将这些技术与糖肽保留时间预测和 UHPLC-QqQ 条件优化结合使用,开发了一种基于动态多重反应监测(dMRM)的策略,以同时监测 50 种血清糖蛋白中的 100 多个糖基化位点。总共同时监测了超过 600 种糖肽的丰度,其中一些糖肽是通过利用理论预测的离子产物和假定的 m/z 值来鉴定的。该 dMRM 方法具有良好的灵敏度。在靶向 dMRM 模式下,9 种标准糖蛋白的定量下限(LOQ)达到飞摩尔水平,动态范围跨越 3-4 个数量级。基于 dMRM 的策略在仪器和样品制备性能方面也表现出很高的重现性。可以定量到糖肽水平的血清糖蛋白的高覆盖率使该方法特别适合从大量样本集中发现生物标志物。我们预计,在不久的将来,这些生物标志物,如癌症和自身免疫等领域,将被临床应用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验